Скачать с ютуб The prognostic value of post-therapy LuPSMA-SPECT/CT in mCRPC в хорошем качестве

The prognostic value of post-therapy LuPSMA-SPECT/CT in mCRPC

Andrei Gafita, MD, Johns Hopkins Medicine, Baltimore, MD, explores the prognostic significance of post-therapy 177Lu-PSMA-617 (LuPSMA)-SPECT/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing LuPSMA radioligand therapy. SPECT/CT after two treatment cycles predicts overall survival, though PSMA-PET/CT identifies a higher number of progressive disease cases. The findings highlight the potential for refining response monitoring protocols in prostate cancer. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.